AstraZeneca ($AZN) began construction this week of the corporate-record-setting manufacturing plant in China Medical City, Jiangsu Province, that it announced in October. The company said at the time that the $230 million financial commitment is its largest for a single manufacturing facility.
AZ expects to produce IV and solid dosage form treatments at the new facility. It will produce both its own branded drugs and branded generics, reports Shanghai Daily.
The plant, expected to be completed in late 2013, adds to AZ's manufacturing portfolio in China, according to the report. Its manufacturing and supply site in Wuxi New District, Jiangsu Province, has been operating since 2001.
The manufacturing capacity for generics aligns with AZ's acquisition in November of privately held generics maker Guangdong Beikang Pharmaceutical.
- see the story